• Dominique GuexEmail author
Part of the LIDC Contributions on Antitrust Law, Intellectual Property and Unfair Competition book series (LIDC)


The pharmaceutical industry is an important sector of the Swiss economy. In 2014, the worldwide turnover realized by pharmaceutical companies headquartered in Switzerland represented more than USD 90 billion, while this sector contributed to one-third of Swiss exports and employed more than 40,000 workers. Comparatively, competition law enforcement has been rather moderate in this sector over the past 15 years. Merger review let aside, a handful of investigations carried out by the Competition Commission led to significant decisions. Among them was the well-known international vitamin price-fixing cartel. The other cases related to the distribution of pharmaceutical products. It seems that Switzerland has not (yet) been caught by the wave of enforcement activity in this sector in the United States or, more recently, in the European Union. The Competition Commission has notably not had to struggle with reverse payment settlements and other issues at the crossroad of intellectual property and competition law.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Bourgeois Avocats SALausanneSwitzerland

Personalised recommendations